FDA warned DirectPharmaShop.net over selling unapproved, misbranded antipsychotics to U.S. consumers online.
What happened
FDA reviewed the website www.directpharmashop.net and found it offering aripiprazole marketed as “Abilify 15mg” tablets and quetiapine marketed as “Seroquel 200mg” tablets to U.S. consumers. FDA said the site sold these prescription antipsychotics without a prescription and offered unapproved new drugs without FDA-approved applications.
What FDA found
The website offered aripiprazole and quetiapine as new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offered prescription antipsychotics without requiring a prescription.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]The drug labeling lacked adequate directions for safe lay use, so the products were misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The unapproved drugs did not qualify for the exemption from adequate-directions labeling.
21 CFR 201.115(a)The website introduced misbranded drugs into interstate commerce by offering them for sale to U.S. consumers.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of specific corrective steps and related documentation. If corrections cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- U.S. consumers buying prescription drugs from foreign websites
- online pharmacies selling to U.S. customers
- companies shipping or supplying drugs into U.S. commerce
This is a summary. Read the original letter on fda.gov.